Registration is open for SOSV’s upcoming health tech VC-Founder matchup. Learn More

ViAn Therapeutics

Topical antiangiogenic peptide for retinal vascular diseases

Team

Juan Pablo Robles

Founder & CEO

Company details

ViAn Therapeutics has developed c4551: an unprecedented antiangiogenic small cyclic peptide in a daily eyedrop for retinal diseases such as diabetic retinopathy and age-related macular degeneration. The company stems from three decades of pioneering research in a prominent angiogenesis and ophthalmology lab at the National University of Mexico. Napoleon Ferrara, a leader in the field of angiogenesis, credited for the discovery of VEG-F, is an advisor to the company. ViAn Therapeutics’ at-home daily eyedrop will disrupt existing modalities involving invasive and costly antibodies and small molecules.

Get In Touch with ViAn Therapeutics

Please tell us a little bit about yourself and why you'd like to get connected. ViAn Therapeutics + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.